Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 August 2000Website:
http://www.curis.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 16:58:13 GMTDividend
Analysts recommendations
Institutional Ownership
CRIS Latest News
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.
Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale Jen - Laidlaw & Co. Operator Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode.
LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.
Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets.
Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.
What type of business is Curis?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
What sector is Curis in?
Curis is in the Healthcare sector
What industry is Curis in?
Curis is in the Biotechnology industry
What country is Curis from?
Curis is headquartered in United States
When did Curis go public?
Curis initial public offering (IPO) was on 01 August 2000
What is Curis website?
https://www.curis.com
Is Curis in the S&P 500?
No, Curis is not included in the S&P 500 index
Is Curis in the NASDAQ 100?
No, Curis is not included in the NASDAQ 100 index
Is Curis in the Dow Jones?
No, Curis is not included in the Dow Jones index
When does Curis report earnings?
The next expected earnings date for Curis is 02 August 2024